ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

benralizumab

Also written as “Benralizumab”, “Benralizumab 100 mg” and “KHK4563”.

Its studies are mostly in Asthma · Pulmonary Disease, Chronic Obstructive · Churg-Strauss Syndrome · Nasal Polyps · Hypereosinophilic Syndrome, led by 2 companies.

Drug pageBenralizumab: every studyAll 67 studies of it, academic ones too, with its approvals, label and forms.
Furthest: phase 4, since Apr 10, 201948 company-led studies, 5 open or runningNext primary completion: Dec 23, 2026 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
AstraZeneca465 open or runningphase 4since Apr 10, 2019Aug 6, 2007Dec 23, 2026phase 3 · NCT05692180
Kyowa Kirinits history only20 open or runningphase 2since Aug 7, 2011Aug 7, 2011none ahead

Also a collaborator on its studies: Parexel, Iqvia Pty, Covance and PPD DEVELOPMENT, LP.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of AstraZeneca only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

Before these, 30 studies since Aug 6, 2007.

  1. Oct 23, 2019Phase 3 study in Nasal PolypsNCT04157335 · 295 enrolled · United States, Argentina, Australia and more
  2. Nov 15, 20192 phase 3 studiesNCT04305405, NCT04191304
  3. Aug 18, 2020Phase 3 study in Eosinophilic EsophagitisNCT04543409 · 211 enrolled · United States, Canada, France and more
  4. Sep 1, 20202 phase 2 studiesNCT04605094, NCT04612725
  5. Oct 12, 2020Phase 3 study in Pemphigoid, BullousNCT04612790 · 67 enrolled · United States, Australia, Bulgaria and more
  6. Jun 23, 2021Phase 3 study in Non-cystic Fibrosis BronchiectasisNCT05006573 · 100 enrolled · United States, Argentina, Australia and more
  7. Aug 6, 2021Phase 3 study in Eosinophilic enteropathyNCT05251909 · 12 enrolled · United States, Brazil, Italy and more
  8. Nov 9, 2021Phase 4 study in In Adult Patients of Severe Asthma With Eosinophilic Phenotype in IndiaNCT05384938 · 139 enrolled · India
  9. Apr 27, 2022Phase 4 study in AsthmaNCT05552508 · 45 enrolled · United States, Australia, Belgium and more
  10. Jan 11, 2023Phase 3 study in AsthmaNCT05692180 · 94 enrolled · United States, Argentina, France and more
  11. Feb 1, 2024Phase 3 study in Pulmonary EosinophiliaNCT06465485 · 504 enrolled · China
  12. Jul 17, 2024Phase 3 study in Churg-Strauss SyndromeNCT06512883 · 14 planned · United States, Brazil, Canada and more
  13. Nov 20, 2024Phase 3 study in Pulmonary EosinophiliaNCT06750289 · 130 enrolled · United States, Bulgaria, Canada and more
  14. Feb 17, 2026Phase 3 study in AsthmaNCT07444567 · 230 planned · United States, Argentina, Austria and more

Ahead

  1. Dec 23, 2026Primary completion: phase 3 study in AsthmaNCT05692180
  2. Feb 20, 2028Primary completion: phase 3 study in Churg-Strauss SyndromeNCT06512883
  3. Dec 27, 2029Primary completion: phase 3 study in AsthmaNCT07444567

TargetBeta

IL5RA →read by rule
“Interleukin-5 receptor subunit alpha inhibitor”ChEMBL 37, by rule

Studies

All 46 AstraZeneca leads, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07444567Asthma · United States, Argentina, Austria and more3RecruitingDec 27, 2029230
NCT06750289Pulmonary Eosinophilia · United States, Bulgaria, Canada and more3CompletedSep 21, 2026130
NCT06512883Churg-Strauss Syndrome · United States, Brazil, Canada and more3RecruitingFeb 20, 202814
NCT06465485Pulmonary Eosinophilia · China3CompletedMay 13, 2026504
NCT05692180Asthma · United States, Argentina, France and more3Active, not recruitingDec 23, 202694
NCT05552508Asthma · United States, Australia, Belgium and more4CompletedJul 19, 202445
NCT05384938In Adult Patients of Severe Asthma With Eosinophilic Phenotype in India · India4CompletedJul 1, 2023139
NCT05251909Eosinophilic enteropathy · United States, Brazil, Italy and more3TerminatedFeb 13, 202412
NCT05006573Non-cystic Fibrosis Bronchiectasis · United States, Argentina, Australia and more3TerminatedApr 16, 2024100
NCT04612790Pemphigoid, Bullous · United States, Australia, Bulgaria and more3TerminatedOct 26, 202367
NCT04612725Chronic Urticaria · United States, Bulgaria, Germany and more2TerminatedOct 13, 2022159
NCT04605094Dermatitis, Atopic · United States, Australia, Bulgaria and more2TerminatedApr 25, 2022194
NCT04543409Eosinophilic Esophagitis · United States, Canada, France and more3TerminatedSep 19, 2022211
NCT04191304Hypereosinophilic Syndrome · United States, Argentina, Austria and more3Active, not recruitingMay 7, 2025134
NCT04305405Asthma · United States, Japan3CompletedSep 12, 202230
NCT04157335Nasal Polyps · United States, Argentina, Australia and more3TerminatedAug 6, 2024295
NCT04159519Asthma · France, Germany, Italy and more4CompletedJan 31, 2023170
NCT04157348Churg-Strauss Syndrome · United States, Belgium, Canada and more3Active, not recruitingAug 10, 2023140
NCT04053634Pulmonary Disease, Chronic Obstructive · United States, Argentina, Australia and more3CompletedJul 28, 2025689
NCT03953300Asthma · United States, Canada, Denmark and more4CompletedOct 20, 202675
NCT03928262Healthy Subjects · Hong Kong1CompletedAug 12, 201936
NCT03557307Asthma · United States, Argentina, Belgium and more3CompletedApr 16, 2021598
NCT03401229Nasal Polyps · United States, Austria, Belgium and more3CompletedJul 31, 2020413
NCT03170271Asthma · United States, Austria, Belgium and more3CompletedSep 25, 2019660
NCT03186209Asthma · China, Korea, Republic of, Philippines and more3CompletedJan 30, 2023695
NCT02968914Asthma · Germany1CompletedJul 13, 2017180
NCT02918071Asthma · United States, Canada3CompletedAug 21, 2017121
NCT02869438Asthma · United States, Chile, Germany and more3CompletedAug 1, 2018233
NCT02821416Asthma · Canada3CompletedOct 22, 201946
NCT02814643Asthma · United States3CompletedJan 24, 2017103
NCT02808819Asthma · United States, Argentina, Australia and more3CompletedJun 18, 2020447
NCT02417961Asthma · United States, Canada3CompletedMar 14, 2016162
NCT02322775Asthma · United States, Canada, Germany and more3CompletedOct 7, 2015211
NCT02258542Asthma · United States, Argentina, Australia and more3CompletedOct 18, 20172,133
NCT02155660Lung Diseases, Obstructive · United States, Argentina, Australia and more3CompletedApr 9, 20182,255
NCT02138916Lung Diseases, Obstructive · United States, Austria, Canada and more3CompletedApr 10, 20181,656
NCT02075255Asthma · United States, Argentina, Bulgaria and more3CompletedAug 8, 2016220
NCT01947946Asthma · United States, Argentina, Brazil and more3TerminatedJul 201413
NCT01928771Asthma · United States, Australia, Brazil and more3CompletedApr 5, 20162,681
NCT01914757Asthma · United States, Argentina, Canada and more3CompletedMar 20162,508
NCT01238861Asthma · United States, Argentina, Brazil and more2CompletedMar 2013964
NCT01227278Pulmonary Disease, Chronic Obstructive · United States, Canada, Denmark and more2CompletedJan 2013421
NCT00783289Asthma · United States2CompletedNov 17, 200935
NCT00768079Asthma · United States, Canada2CompletedDec 17, 2010110
NCT00659659Asthma · United States, Canada1CompletedJan 201127
NCT00512486Asthma · United States1CompletedSep 200842

How it is read

Names in the registry

  • “Benralizumab”, 38 entries
  • “benralizumab”, 3 entries
  • “Benralizumab 100 mg”, 3 entries
  • “KHK4563”, 3 entries
  • “MEDI-563”, 3 entries

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.